Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said, it will invest €72 million to expand its Respimat filling operations in Ingelheim.
The Boehringer Ingelheim microParts site in Dortmund currently employs more than 550 people, and company says that it expects the expansion to create 100 new jobs.
BI’s Wolfgang Baiker, member of the Board of Managing Directors for Operations commented, “The Respimat is a success story – for Boehringer Ingelheim and for the patients. We want to continue this success story. The Respimat inhaler will also in future be the inhalation device for applying our respiratory medications.”
Spiriva Respimat and Striverdi Respimat were both recently approved by the FDA. The company also filed an NDA for tiotropium/olodaterol Respimat in August 2014.
Read the Boehringer Ingelheim press release.
